ClinicalTrials.gov
public full text
Public Domain
Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women
This study is a randomized, double-blind, placebo-controlled, adaptive design, multi-center study of the long-term cardiovascular and breast safety of LibiGel in the treatment of HSDD in postmenopausal women with at least two points of cardiovascular risk and clinical diagnosis of Hypoactive Sexual Desire Disorder (HSDD).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Safety and Efficacy of LibiGel® for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women#868723
- Efficacy Study of Lisdexamfetamine to Treat Binge Eating Disorder#856725
- Female Sexual Dysfunction : Low desire, arousal difficulties, orgasm difficulties, pain during sex, hormonal factors, psychological factors, medications, relationship factors, treatment approaches / Wrenford Vellmont#487281
- A Study to Test How Healthy Women Tolerate Different Doses of BI 1819479#882856
- Does DHEA Enhance the Effects of Exercise in Postmenopausal Women?#869959
Record · ID 854931
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive